title: Outcomes among 562 recipients of placental-blood transplants from unrelated donors.
abstract: BACKGROUND
  A program for banking, characterizing, and distributing placental blood, also called umbilical-cord blood, for transplantation provided grafts for 562 patients between August 24, 1992, and January 30, 1998. We evaluated this experience.
  
  
  METHODS
  Placental blood was stored under liquid nitrogen and selected for specific patients on the basis of HLA type and leukocyte content. Patients were prepared for the transplantation of allogeneic hematopoietic cells in the placental blood and received prophylaxis against graft-versus-host disease (GVHD) according to routine procedures at each center.
  
  
  RESULTS
  Outcomes at 100 days after transplantation were known for all 562 patients, and outcomes at 1 year for 94 percent of eligible recipients. The cumulative rates of engraftment among the recipients, according to actuarial analysis, were 81 percent by day 42 for neutrophils (median time to engraftment, 28 days) and 85 percent by day 180 for platelets (median, day 90). The speed of myeloid engraftment was associated primarily with the leukocyte content of the graft, whereas transplantation-related events were associated with the patient's underlying disease and age, the number of leukocytes in the graft, the degree of HLA disparity, and the transplantation center. After engraftment, age, HLA disparity, and center were the primary predictors of outcome. Severe acute GVHD (grade III or IV) occurred in 23 percent of patients, and chronic GVHD occurred in 25 percent. The rate of relapse among recipients with leukemia was 9 percent within the first 100 days, 17 percent within 6 months, and 26 percent by 1 year. These rates were associated with the severity of GVHD, type of leukemia, and stage of the disease.
  
  
  CONCLUSIONS
  Placental blood is a useful source of allogeneic hematopoietic stem cells for bone marrow reconstitution.
authors.affiliation: F.H. Allen Laboratory of Immunogenetics, New York Blood Center, NY 10021, USA.
authors.forename: P
authors.initials: P
authors.lastname: Rubinstein
authors.forename: C
authors.initials: C
authors.lastname: Carrier
authors.forename: A
authors.initials: A
authors.lastname: Scaradavou
authors.forename: J
authors.initials: J
authors.lastname: Kurtzberg
authors.forename: J
authors.initials: J
authors.lastname: Adamson
authors.forename: A R
authors.initials: AR
authors.lastname: Migliaccio
authors.forename: R L
authors.initials: RL
authors.lastname: Berkowitz
authors.forename: M
authors.initials: M
authors.lastname: Cabbad
authors.forename: N L
authors.initials: NL
authors.lastname: Dobrila
authors.forename: P E
authors.initials: PE
authors.lastname: Taylor
authors.forename: R E
authors.initials: RE
authors.lastname: Rosenfield
authors.forename: C E
authors.initials: CE
authors.lastname: Stevens
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005069:Evaluation Studies as Topic; D005260:Female; D005312:Fetal Blood; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology; D006402:Hematologic Diseases / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000628:therapy; D007958:Leukocyte Count; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017063:Outcome Assessment, Health Care; D010920:Placenta / Q000098:blood supply; D012008:Recurrence; D012306:Risk